Drug Trial Radar · NCT06188455
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Dec 1, 2024
Primary completion
Dec 1, 2025
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Xiamen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled
Conditions
- Ovarian Cancer
Interventions
Fluzoparib CapsulesDrug
Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily
Apatinib Mesylate TabletsDrug
Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: up to12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.